Efficacy and safety of endostar combined with chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer: A PRISMA-compliant systematic review and meta-analysis

Abstract

Background: To evaluate the role and safety of endostar in cervical cancer by comparing the efficacy and adverse reactions of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma.Methods: The quality of the included literature was evaluated by searching the database for the comparison of endostar combined with concurrent radiotherapy and chemotherapy in cervical cancer patients; objective response rate (ORR) and disease control rate (DCR) were used as the main outcome indicators, and statistical analysis was performed using RevMan5.3 and State15.3 software.Results: A total of 13 studies were included in this study, including 1057 patients with locally advanced cervical cancer, suggesting that endostar combined with chemoradiotherapy can significantly improve the objective response rate (ORR: odds ratio 3.88, 95% confidence interval 2.77-5.45, P < .00001) and disease control rate (DCR: odds ratio 4.43, 95% confidence interval 2.78-7.04; P < .00001), and there was no significant increase in treatment-related adverse reactions.Conclusions: In this meta-analysis, endostar combined with concurrent chemoradiotherapy significantly improved ORR and DCR in patients with locally advanced cervical cancer without increasing toxicity. However, this study only analyzed the shortterm efficacy of endostar, and its influence on overall survival and progression-free survival needs to be further verified in large randomized controlled trials with long-term follow-up.Abbreviations: CCRT = concurrent chemoradiotherapy, CR = complete response, CI = confidence interval, DCR = disease control rate, NOS = Newcastle-Ottawa Scale, NRCT = non randomized controlled trial, ORR = objective response rate, PDGF = platelet-derived growth factor, PFS = progression-free survival, PRISMA = priority report item for systematic review and metaanalysis, RCT = randomized controlled trial, VEGF = vascular endothelial growth factor.

A Reconfigurable DNA Framework Nanotube-Assisted Antiangiogenic Therapy

“…Antiangiogenic therapy, which targets tumor blood vessels-related molecules for inhibiting the growth of tumor blood vessels and the development of tumors has emerged as one of the most attractive cancer treatment strategies. , With the burgeoning development of antiangiogenic therapy, a multitude of antiangiogenic drugs have been applied to cancer treatment in clinic or in basic studies. , These antiangiogenic drugs have remarkably prolonged the survival time of cancer patients, and their combination with the first-line chemotherapeutic drugs even contributed to the definition of some certain cancers toward a chronic disease owing to the synergistic effects. − However, antiangiogenic drugs often cause multiorgan injury, such as hepatotoxicity and cardiotoxicity due to their poor tumor-targeting performance and nonspecific biodistribution, which finally makes the cancer patients suffer tremendously. − In this regard, developing a robust platform, capable of facilitating the tumor targeting of antiangiogenic drugs and simultaneously reducing their cumulation in normal tissues, is highly desirable and a precondition for circumventing multiorgan injury.…”

Anti(angiogenic) food components: can be a major source of bias in the investigation of angiogenesis inhibitors

“…The potential of angiogenesis inhibitors or angiogenesis modulating agents as therapy in a wide range of cancers such as ovarian cancer ( 1 ), metastatic thyroid cancer ( 2 ), metastatic colorectal cancer ( 3 ), metastatic kidney cancer ( 4 ), cervical cancer ( 5 ), stromal tumors ( 6 ) has increased dramatically over the past 20 years by newly emerged clinically available agents. To mention a few, a similar trend is seen for other angiogenesis-related diseases such as retinal neovascularization and corneal neovascularization ( 7 - 9 ).…”